Compare ACADIA Pharmaceuticals Inc. (ACAD) vs British American Tobacco PLC (BTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs British American Tobacco PLC — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while British American Tobacco PLC trades at $61.67 (market cap $132.11B). The key difference: British American Tobacco PLC is far larger — about 29.4× ACADIA Pharmaceuticals Inc.'s market cap, and British American Tobacco PLC pays a 5.4% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BTI | |
|---|---|---|
Market Cap | $4.49B | $132.11B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $66.70 |
52-Week Low | $20.06 | $47.93 |
Enterprise Value | $3.69B | $173.34B |
Dividend Yield | — | 5.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
British American Tobacco (BTI) trades at $61.80, up 0.05% on the day, with a bullish technical signal from moving averages and strong support at $61. The company shows robust profitability with a 30.32% net income margin and a 15.74% ROE, though revenue declined to $25.87B in 2024. Recent news highlights a major restructuring with 5,500 job cuts to drive cost savings and growth in non-traditional products like Velo nicotine pouches (Reuters, 2026-06-29).
BTI offers a compelling value with a P/E of 13.34 and a 5%+ dividend yield, supported by 66.7% analyst buy ratings. Key risks include regulatory pressures from the FDA's proposed oversight of foreign tobacco makers (Reuters, 2026-06-26) and volatile earnings, as seen in a 2023 net loss. The stock's outlook is positive for income-focused investors, balancing high margins with transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
